openPR Logo
Press release

Investigation announced for Investors in shares of Repare Therapeutics Inc. (NASDAQ: RPTX) over possible Breaches of Fiduciary Duties

04-21-2023 03:26 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Repare Therapeutics Inc. (NASDAQ: RPTX) shares over potential wrongdoing.

An investigation on behalf of investors in Repare Therapeutics Inc. (NASDAQ: RPTX) shares over potential wrongdoing.

An investigation was announced over potential breaches of fiduciary duties by certain directors at Repare Therapeutics Inc.

Investors who purchased shares of Repare Therapeutics Inc. (NASDAQ: RPTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Repare Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.

Montreal, Canada based Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States.

On or around June 18, 2020, Repare Therapeutics Inc. conducted its initial public offering ("IPO"), issuing 11 million shares of common stock priced at $20.00 per share.

On February 3, 2023, Morgan Stanley analyst Jeffrey Hung downgraded Repare Therapeutics Inc. to Equal Weight from Overweight. Hung cited concerns over an upcoming Phase 1 readout for the Company's PKMYT1 inhibitor RP-6306, noting that "PKMYT1 is a novel target" and opining that initial Phase 1 data for RP-6306 will focus on Pharmacokinetics, Pharmacodynamics, and proving target inhibition.

Shares of Repare Therapeutics Inc. (NASDAQ: RPTX) declined to as low as $8.53 per share on April 11, 2023.

Those who purchased shares of Repare Therapeutics Inc. (NASDAQ: RPTX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Repare Therapeutics Inc. (NASDAQ: RPTX) over possible Breaches of Fiduciary Duties here

News-ID: 3022942 • Views:

More Releases from Shareholders Foundation

Investigation announced for Investors in Treace Medical Concepts, Inc. (NASDAQ: TMCI) over potential Wrongdoing
Investigation announced for Investors in Treace Medical Concepts, Inc. (NASDAQ: …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Treace Medical Concepts, Inc. Investors who purchased shares of Treace Medical Concepts, Inc. (NASDAQ: TMCI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Treace Medical Concepts, Inc. directors breached their fiduciary duties and caused damage to the company and its
Deadline on May 20th coming up in Lawsuit for Investors in the Chemours Company (NYSE: CC)
Deadline on May 20th coming up in Lawsuit for Investors in the Chemours Company …
A deadline is coming up on May 20, 2024 in the lawsuit filed for certain investors of The Chemours Company (NYSE: CC) over alleged securities laws violations by The Chemours Company. Investors who purchased shares of The Chemours Company (NYSE: CC) have certain options and there are strict and short deadlines running. Deadline: May 20, 2024. NYSE: CC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Lawsuit filed for certain Investors who lost money with shares of Global Cord Blood Corporation (OTC: CORBF)
Lawsuit filed for certain Investors who lost money with shares of Global Cord Bl …
An investor, who purchased shares of Global Cord Blood Corporation (OTC: CORBF), filed a lawsuit over alleged violations of Federal Securities Laws by Global Cord Blood Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Global Cord Blood Corporation (OTC: CORBF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. OTC: CORBF investors should contact the Shareholders
Lawsuit filed for Investors who lost money with shares of Autodesk, Inc. (NASDAQ: ADSK)
Lawsuit filed for Investors who lost money with shares of Autodesk, Inc. (NASDAQ …
An investor, who purchased shares of Autodesk, Inc. (NASDAQ: ADSK), filed a lawsuit over alleged violations of Federal Securities Laws by Autodesk, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Autodesk, Inc. (NASDAQ: ADSK) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. NASDAQ: ADSK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)

All 5 Releases


More Releases for Repare

DNA Repair Drugs Market Growth Forecast from 2022 to 2028 | Worldwide Industry A …
A new market study on the 2022-2028 DNA Repair Drugs Market with 100+ market data Tables, Pie Chat, and Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry-validated market data. The report incorporates a broad evaluation
DNA Repair Drugs Market is expected to exhibit a CAGR of 32.4% Major Players Ana …
DNA repair drugs are widely utilized for repairing damaged DNA, as well as for treating various types of cancer. DNA damage results usually in genetic disorders; however, the human body has its own mechanisms to correct the DNA sequence. DNA repair drugs, such as PARP inhibitors and other DNA repair drugs, help in the treatment of diseases with genetic aberrations. The global DNA repair drugs market was evaluated at US$ 461.3
Global RNA Polymerase Inhibitors Market Growth Analysis, Latest Trends and Forec …
An RNA polymerase (RNAP), also known as ribonucleic acid polymerase, is a multi-subunit enzyme that catalyzes the transcription process, which results in the formation of an RNA polymer from a DNA template. Any disruption in the enzyme's normal action can result in a variety of diseases, including breast cancer, ovarian cancer, lung cancer, and others. The global RNA Polymerase Inhibitors market size is projected to reach US$ XX million by
DNA Repair Drugs Market – Breakthrough for Cancer Patients
DNA repair drugs such as Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna) are used for treating ovarian and breast cancer. These drugs fall under the category of Poly ADP-ribose Polymerase (PARP) inhibitors used as monotherapy in combination with other drugs for treatment of cancer. Request Here PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2617 Market Dynamics Increasing incidences of cancer, increasing collaboration and acquisition with product launch by market players are major
PARP Inhibitor Market Covid19 Impact - AstraZeneca Plc., Johnson & Johnson, Glax …
Coherent Market Insights announced that it’s published an exclusive report namely Global PARP Inhibitor Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide PARP Inhibitor Market. This is an informative study covering
PARP Inhibitors Market To Record An Exponential CAGR By 2028 | Johnson & Johnson …
InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on “Global PARP Inhibitors Market Assessment – Revenue (US$ Mn) Forecast Till 2028” Request for Sample Pages: https://www.insightaceanalytic.com/report-details/global-parp-inhibitors-market-assessment/ According to the latest research by InsightAce Analytic, the global market for PARP inhibitors is expected to record a promising CAGR during the period of 2020-2028. PARP inhibitors are a collection of pharmacological inhibitors of the enzyme poly ADP ribose polymerase. They